Reference Pbmc
-
Upload
ikoppandi -
Category
Technology
-
view
424 -
download
3
description
Transcript of Reference Pbmc
![Page 1: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/1.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Cryopreserved human PBMC libraries with defined HLA-type and antigen / peptide-reactivity for accelerating and standardizing human immunological research.
![Page 2: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/2.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Step 1 towards standardization: Functionally loss-free freezing of PBMC
In 2003 CTL scientists introduced protocols for functionally loss-free freezing of PBMC:
Kreher et al. : CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J. Immunol. Methods, 278:79-93, 2003
(IFN-γ, IL-2, IL-4 and IL-5 were measured)
![Page 3: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/3.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
1a. The role of temperature:Blood should be shipped, stored, and processed all times at room
temperature, not chilled. For freezing, the cells and the DMSO-containing cryomedium must be at room temperature (not ice-cold) when mixed. When thawing, bring cells rapidly to 37 oC.
Live
Apoptotic
Dead
![Page 4: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/4.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
1b. Following this protocol, we found that high and low frequency, high and low avidity T cells are preserved, loss free. No “resting” needed after thawing.
NIAID Contr. HHSN266200400098I, ELISPOT Qualification, Vaccinia
Ex vivo/ Ex cryo
![Page 5: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/5.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
• Since 2005, CTL offers a reference PBMC library, presently consisting of over 70 PBMC donors to chose from, each• High resolution HLA-typed (Class I and Class II)
• Immune-characterized for• 20 antigens, recognized by CD8 and CD4 cells
• IFN-γ, IL-2, IL-4, IL-5, IL-17, Granzyme B
• High and low frequency T cell responses
• High and low avidity T cell responses
• Essentially unlimited availability of identical cell material: between 500 and 1,000 aliquots of 10 million PBMC/vial from each donor available from each draw.
• Reference PBMC are essential for assay comparisons, qualification/ validation, and harmonization across institutions
Step 2 towards standardization: Reference PBMC
![Page 6: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/6.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Example: response profile of donor 19
LP-19
Peptide Conc. (Log M)
-12 -11 -10 -9 -8 -7 -6 -5 -4
SP
U/4
00
,00
0 P
BM
Cs
0
100
200
300
400
500
600
700
CEF-3CEF-4CEF-5CEF-6CEF-7sigmoidal dose-response (variable slope)
![Page 7: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/7.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
• In 2005, CTL introduced serum free media for all steps of PBMC processing and testing • Freezing (CTL-Cryo™)
• Thawing (CTL-Deaggregate ™)
• Washing (CTL-Wash ™)
• Testing (CTL-Test ™)
Since, we and our customers have seen no serum that performs significantly better, but many sera that perform (much) worse.
Step 3 towards standardization: Serum Free Media
![Page 8: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/8.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Wouldn't if be fantastic if you...
• Did not need to chase your colleagues with a needle anymore to obtain some peripheral blood mononuclear cells (PBMC) for your experiments?
![Page 9: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/9.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Wouldn't if be fantastic if you...
• Did not need to bother with IRBs just to obtain some blood from healthy volunteers because we have taken care of this for you?
![Page 10: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/10.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Wouldn't if be fantastic if you...
• Can do experiments that you have never done before because you can obtain as many PBMC as you need (up to 10 billion cells from the same donor at the same time of bleed)?
![Page 11: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/11.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Wouldn't if be fantastic if you...
• Can immediately repeat experiments with PBMC of the same donor and of the same bleed, if the reviewer asks you to provide that one additional control?
![Page 12: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/12.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Wouldn't if be fantastic if you...
• Can share the same PBMC with collaborators anywhere on the planet?
![Page 13: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/13.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Wouldn't if be fantastic if you...
• Can prepare PBMC for an experiment more simply and more quickly than isolating such cells from blood by yourself?
![Page 14: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/14.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Wouldn't if be fantastic if you...
• Have immediate access to a library of PBMC that are pre-characterized, with established HLA-types and antigen reactivities?
![Page 15: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/15.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Wouldn't if be fantastic if you...
• Can design your experiments by selecting test subjects from a panel of characterized human donors?
![Page 16: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/16.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Wouldn't if be fantastic if you...
• Can use such pre-characterized cells as positive and negative controls for any immune monitoring effort, and as reference samples to control the consistent performance of your assays?
![Page 17: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/17.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Wouldn't if be fantastic if you...
• Have access to a large number of human donors that you can screen for an immune reactivity and/or genetic marker of your own individual interest?
![Page 18: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/18.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Wouldn't if be fantastic if you...
• Do not have to worry about the human material you work with is HIV , Hepatitis B, etc infected?
![Page 19: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/19.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
CTL has made this dream come true by offering immune characterized cryopreserved PBMC libraries!
![Page 20: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/20.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Identifying reference PBMC samplesIL-2 responses to CMV antigen in human PBMC donors
0
50
100
150
200
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Sample
IL-
2 s
po
ts / 4
00
,00
0 c
ells
IL-4 responses to CMV antigen in human PBMC donors
0
50
100
150
200
250
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Sample
IL-
4 s
po
ts / 4
00
,00
0 c
ells
Utilization of ePBMC for ELISPOT assay development, qualification and validation Single color human, murine and macaque IFN-γ assay, Vaccinia/MVA- specific NIAID ContrNo. HHSN266200400098I, highlights
![Page 21: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/21.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
Vaccinia WR virus titration
Vaccinia WR virus concentration
4m
oi2m
oi
1 m
oi
0.5
moi
0.25
moi
0.12
5 m
oi
0.06
2 m
oi
0.03
1 m
oi
0.01
5 m
oi
0.00
7 m
oi
0.00
3 m
oi
0.00
1 m
oi
No.
IF
N
spot
s/40
0,00
0 ce
lls
0
50
100
150
200
250CS180 CS189 321050806P 318050806V 20060706A
a. Optimal antigen dose
![Page 22: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/22.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
b. Accuracy
![Page 23: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/23.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
c. Linearity (and range)
r=0.998
![Page 24: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/24.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
d. Precision –
Inter assay repeatability
![Page 25: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/25.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
e. Precision
Intermediate precision
(using low responder)
![Page 26: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/26.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 6 12 18 24 30 36 42 48Duration of CMV stimulation (h)
% M
ax
imu
m S
po
t N
um
be
r
IFN-g IL-2IL-4IL-17
Kinetics of cytokine production after CMV stimulation
![Page 27: Reference Pbmc](https://reader033.fdocuments.net/reader033/viewer/2022061202/547cabb1b4af9fa9438b4665/html5/thumbnails/27.jpg)
(c) 2009 Cellular Technology Limited- CONFIDENTIAL -
IL-2
0
50
100
150
200
250
r =0.998
IL-4
050
100150200250300350400450500
r =0.998
IL-17
0
10
20
30
40
50
60
70
r =0.956
TNTC
Number of PBMC per Well
SF
U p
er
We
ll
IFN-g
0
50
100
150
200
250
300
350
400
450
r =0.937
Linearity of CMV induced cytokine spots